Insider Buying: Frank Stokes Acquires Shares in XGN
Frank Stokes purchased 37,500 shares of XGN, joining recent insider activity.
Key Points
- Frank Stokes bought 37,500 shares of XGN on June 9, 2026, as the stock traded at $4.45.
- XGN has seen varied institutional interest, with some funds increasing and others reducing their holdings.
- Analysts have maintained a positive outlook, with several firms keeping a 'buy' rating on XGN.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
On June 9, 2026, Frank Stokes made a significant purchase of 37,500 shares of XGN. The transaction, which did not occur under a pre-planned trading program, adds to the recent insider activity around the company. XGN shares were trading near $4.45 on Monday.
Insider Buying and Selling at Exagen Inc.
Frank Stokes wasn't alone in his insider activity. Earlier this year, John Aballi, the President and CEO, acquired a total of 250,000 shares on March 12, 2026, at an average price of $3.16. Additionally, Jeffrey Black, the Chief Financial Officer, purchased 125,000 shares on the same date, also at $3.16 per share. These transactions reflect a continued insider interest in the company's stock.
Other Institutional Activity in XGN
There has been notable institutional movement in XGN recently. Balysany Asset Management L.P. reduced its holdings by 122,555 shares, bringing its total to 796,632 shares worth approximately $2.39 million. In contrast, Wexford Capital LP increased its position by 326,077 shares, ending with 792,855 shares valued at about $2.38 million. Acadian Asset Management LLC also boosted its holdings by 274,666 shares, resulting in 689,114 shares worth $2.06 million. Meanwhile, Vanguard Capital Management LLC opened a new position with 678,652 shares valued at $2.04 million.
Analysts Set New Price Targets
Analysts have shown consistent confidence in XGN. On May 12, 2026, BTIG maintained its 'buy' rating with a price target of $8. Earlier, on April 20, Canaccord Genuity also upheld a 'buy' rating with the same target. Multiple firms, including Craig-Hallum and Keybanc, have similarly maintained 'buy' ratings, with targets reaching up to $10.
Bottom Line
The recent insider purchase by Frank Stokes adds to a series of acquisitions by company executives, suggesting confidence in XGN's future. Institutional investors show mixed actions, with some increasing and others decreasing their stakes. Analysts remain optimistic, maintaining 'buy' ratings with targets as high as $10. While insider transactions can be insightful, they are backward-looking and may not reflect current sentiment.
Get Exagen Inc. alerts
New 13F filings, insider trades, and analyst moves on $XGN, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.